MD&A Q3_2020 (Eng ) November 2, 2020 Subject : Interim Management Discussion and Analysis of Q3/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial
April 27th, 2021 No. ACC/HO 008/64 Topic: Management Discussion and Analysis for the Quarter of 1/2021 To: President The Stock Exchange of Thailand During the first quarter of 2021 a new wave of
Microsoft Word - MD&A-E-mh-FA-nn.docx 1 Ref: CSO 016/2020 Date: 7th May 2020 Subject: Management Discussion and Analysis Quarter 1 Ending 31st March 2020 Attention: President The Stock Exchange of
August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries
-9320 1 Ref: PCL 2020/018 November 14, 2020 Subject: Management Discussion and Analysis for the 9-month period ended 30 September 2020 To: The President of the Stock Exchange of Thailand Panjawattana
MDA Q3_2019 (Eng ) November 8, 2019 Subject : Interim Management Discussion and Analysis of Q3/2019 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements
organizations, i.e., the Stock Exchange of Thailand (SET), the Federation of Accounting Professions under the Royal Patronage, the Thai Institute of Directors, the Thai Listed Companies Association, the MAI
Baht 50 million in Q1’2018 to Baht 53 million in Q2’2018, primarily attributable to profits at our associate and our joint ventures namely BGYSP and BGSENA. Gain (Loss) on Exchange Rate • Recorded Gain
consecutive years. However, the company’s securities has selected in the SET High Dividend 30 Index or SETHD from the Stock Exchange of Thailand which the price index reference 30 shares group in the SET100